|
|
|
European Biopharmaceutical Review
|
| Pharmaceutical companies are facing a new kind of challenge: breakthrough biotech products that are so successful they overwhelm manufacturing capacity. With biological manufacturing set-up costs in the hundreds of millions of dollars per product, it is a tough call to predict market success correctly. Aiming too high in capacity means that costs may never be recovered. On the other hand, with set-up times for new facilities often extending to three or four years, planning capacity too low can mean years of short supply. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Geoff Tomlinson, Principal, and Hannes Kunz, Director of PRTM
Geoff Tomlinson is a Principal in the Life Sciences Practice of global management consultants PRTM. His consulting experience includes work with companies across Europe and the US on supply chain management, marketing and sales initiatives. These engagements have covered a range of industries including pharmaceutical, medical devices and diagnostics, and consumer goods.
Prior to consulting, Geoff worked in management positions for Rank Hovis McDougall in sales, production and quality. He holds a degree in Biological Sciences from Exeter University and has an MBA from Manchester Business School.
Hannes Kunz is a Director in the Life Sciences Practice of global management consultants PRTM. Hannes has led numerous projects with companies across a range of industry sectors, including life sciences. He has extensive experience in facilitating emerging and global companies to deliver value to their customers through their product strategies and product development excellence, e-business, marketing and CRM.
Prior to joining PRTM, Hannes was a Director at a consulting firm with the responsibility for customer relationship management, e-commerce consulting and implementation services for German-speaking countries. Hannes holds degrees in both Law and Economics from the University of Zurich.
|
|
|
|
|
|
 |
Industry Events |
 |
BIO-Europe Spring® 2012 — 6th International Partnering Conference
19-21 March 2012, Amsterdam RAI Convention Center, Amsterdam, The Netherlands
BIO-Europe Spring is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe, and continues the tradition of providing life science companies with high caliber partnering opportunities. Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.
More info >> |
|
 |
News and Press Releases |
 |
Greenphire and Merge Healthcare Form Exclusive Partnership to Integrate Clinical Payment and EDC Platforms
Greenphire announced today that it has
formed an exclusive strategic partnership with the clinical trials division of
Merge Healthcare (NASDAQ: MRGE), a leading provider of clinical
trial solutions, to offer integrated functionality between Merge’s EDC
technology and Greenphire’s eClinicalGPS site and vendor payment management
technology.
More info >> |
|
|
